Showing 901-910 of 1046 results for "".
- FCI Ophthalmics Announces Availability of LacriJet for Monocanalicular Nasolacrimal Intubationhttps://modernod.com/news/fci-ophthalmics-announces-availability-of-lacrijet-for-monocanalicular-nasolacrimal-intubation/2478907/FCI Ophthalmics announced the launch of the LacriJet in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single use injector, according to FCI Ophthalmics. LacriJet consists of a single use injector handpiece into which a silicone tu
- Johnson & Johnson Vision Reveals New Data on Blue-Violet Light Filtering Technology in Acuvue Oasys Max 1-Day Contact Lenseshttps://modernod.com/news/johnson-johnson-vision-reveals-new-data-on-blue-violet-light-filtering-technology-in-acuvue-oasys-max-1-day-contact-lenses/2481196/Johnson & Johnson Vision Care will present new data on the positive effects of wearing blue-violet light filtering contact lenses at the 2022 American Academy of Optometry (AAO) annual meeting in San Diego, October 26-29. "As a result of our increasingly digital
- Bausch + Lomb Announces New Scientific Analyses Featuring Surgical And Pharmaceutical Products Will Be Presented During ASCRShttps://modernod.com/news/bausch-lomb-announces-new-scientific-analyses-featuring-surgical-and-pharmaceutical-products-will-be-presented-during-ascrs/2476509/Bausch + Lomb announced that 26 new scientific analyses, including 23 podium presentations and three posters, will feature the company’s surgical and pharmaceutical products during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in San Diego from
- Vision Plan Customer Satisfaction Increases, J.D. Power Findshttps://modernod.com/news/vision-plan-customer-satisfaction-increases-j-d-power-finds/2477073/Overall customer satisfaction among vision plan members has increased in 2019, driven by improved perceptions of value and coverage. According to the J.D. Power 2019 Vision Plan Satisfaction Report, overall satisfaction increased by 17 points (on a 1,000-point scale) to 770 this year from 753 in
- Visual Cortical Prosthesis Is Tested at Baylor College of Medicinehttps://modernod.com/news/visual-cortical-prosthesis-is-tested-at-baylor-college-of-medicine/2476698/In a dark room inside Baylor College of Medicine, study participants are asked to look at a blacked out computer screen and point to a white square that appears at intervals on different locations on the monitor. The majority of the time they can successfully point to the square, even though each
- The Vision Council Opens Registration for 2026 Executive Summithttps://modernod.com/news/the-vision-council-opens-registration-for-2026-executive-summit/2484153/The Vision Council announced that registration is open for the 2026 Executive Summit. The 3-day forum will be held January 26-28, 2026, at The Ritz-Carlton, Amelia Island, Florida.
- Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposiumhttps://modernod.com/news/abstract-on-zeta-1-study-of-apx3330-receives-award-at-women-in-ophthalmology-wio-summer-symposium/2481795/Ocuphire Pharma announced that data from its phase 2 clinical trial of APX3330 in diabetic retinopathy (DR) were featured in an oral presentation on Saturday, August 26 at the
- Eyenovia Announces Poster Presentation at ASCRS 2022https://modernod.com/news/eyenovia-announces-poster-presentation-at-ascrs-2022/2480776/Eyenovia announced that the company will present an ePoster at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which is being held April 23-26 in Washington, D.C. Details of the ePoster presentation are as follows: <
- Graybug to Present at the 2022 ASCRS Annual Meetinghttps://modernod.com/news/graybug-to-present-at-the-2022-ascrs-annual-meeting/2480770/Graybug Vision announced a platform presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, to be held in Washington, D.C. from April 22-26, 2022. Information is listed below and available on the
- China Gives Green Light to Allergan’s Xen Registration for the Surgical Management of Refractory Glaucomahttps://modernod.com/news/china-gives-green-light-to-allergans-xen-registration-for-the-surgical-management-of-refractory-glaucoma/2477514/Allergan announced China’s National Medical Products Administration (NMPA) approved the registration of Allergan’s Xen Gel Stent on March 26, 2020 for the surgical management of patients with refractory glaucoma. Xen is th